Share on facebook Share on Twitter Share on Google Plus Share This

Cancer Center

The New England Cancer Moonshot Summit

About the Cancer Moonshot Summit

The Cancer Moonshot Summit is aimed at creating action and fostering collaborations around the goals of the Cancer Moonshot. The Cancer Moonshot Summit will be the very first time that stakeholders representing all types of cancers will convene under one national charge.

Attendees at Summits across the nation include leaders representing the entire cancer community – including researchers, doctors, scientists, philanthropists, community oncologists, advocates, patients, and survivors.

Thank you for joining us at one of hundreds of summits held around the country in conjunction with the Cancer Moonshot Summit held in Washington, DC. The goal of the Cancer Moonshot is to double the rate of progress in cancer prevention, diagnosis, treatment and care over the next five years and to ultimately end cancer as we know it. 


  • To open dialogue and encourage collaborations for accelerating the pace of progress in cancer research, prevention, treatment, and care
  • To create and strengthen relationships to continue the conversation on progressing toward a cure for cancer
  • To discover ways in which big data can contribute to forward progress
  • To deliberate how care and access to care can be enhanced for patients
  • To generate ideas and commitments to accelerate cures and end cancer as we know it 

Video recap

12:00 PM Registration
12:30 PM Welcome
Murat A. Anamur, MD Lowell General Hospital
Andrew M. Evens, DO, MSc, FACP Tufts Medical Center
Tracey F. Weisberg, MD New England Cancer Specialists
12:45 PM Remarks from Vice President Joe Biden
1:15 PM Panel Discussion: The Impact of Cancer Foundations Towards Success of the National Cancer Moonshot
Tracey F. Weisberg, MD, New England Cancer Specialists
Dana A. Callow, Jr. Leukemia and Lymphoma Society
Meghan Gutierrez, CEO, Lymphoma Research Foundation
Neil Maniar, PhD, MPH, American Cancer Society
Lorraine and Gene Sacco, C-Founders, Reid R. Sacco Adolescent and Young Adult Cancer Alliance
Randy Schwartz, MSPH, American Cancer Society
2:00 PM Break
2:10 PM Panel Discussion: Disrupting the Status Quo to Accelerate More Cures for Cancer
Murat A. Anamur, MD Lowell General Hospital
Andrew M. Evens, DO, MSc, FACP, Tufts Medical Center
Tariq Mughal, MD, Foundation Medicine
Abhi Pandey, MD, Syapse
Dvorit Samid, PhD, NantKwest
Andy Dorner, PhD, Takeda Oncology
2:55 PM Break
3:05 PM  Panel Discussion: Levering Unique Resources for Cancer Precision Medicine
Andrew M. Evens, DO, MSc, FACP, Tufts Medical Center
Anthony P. Monaco, PhD, Tufts University
Deborah T. Kochevar, DVM, PhD, DACVC, Tufts Cummings School of Veterinary Medicine
Harry Selker, MD, MSPH, Tufts University School of Medicine
3:50 PM Closing Remarks
Murat A. Anamur, MD Lowell General Hospital
Andrew M. Evens, DO, MSc, FACP Tufts Medical Center
Tracey F. Weisberg, MD New England Cancer Specialists

Murat A. Anamur, MD
Medical Director of Cancer Services and Chairman, Cancer Committee
Lowell General Hospital Cancer Center

Dr. Murat Anamur is a Board Certified Hematologist and Oncologist practicing in Lowell, Massachusetts since 1990. He received his medical training at the University of Istanbul Medical School, residency in Internal Medicine at Cook County Medical Center and his fellowship training in Hematology and Oncology at Brown University and is currently an Assistant Clinical Professor at Tufts University Medical School. During his tenure in the Lowell community, he has developed comprehensive cancer programs including multidisciplinary disease specific clinics for patients with Urologic, Breast, ENT and Lung Cancer, emphasizing the importance of the team approach to cancer care. As the Medical Director of the Cancer Center at Lowell General Hospital over the past 10 years, Dr. Anamur has also brought clinical trials to the Lowell Community and continues to develop guidelines for survivorship and palliative care programs. In addition to his role as Medical Director, he is the Chair of the Cancer Committee and Tumor Board of Lowell General Hospital.

Dana A. Callow, Jr. 
Board Member
Leukemia and Lymphoma Society

Mr. Callow is a founder and Managing Partner of Boston Millennia Partners. Prior to forming Boston Millennia Partners, Mr. Callow co-founded Boston Capital Ventures in 1982 and is a Partner in four of its investment partnerships. Prior to that, he worked as a Senior Consultant at Braxton Associates, an international strategic planning firm that was organized by professionals from Boston Consulting Group and Bain & Co. His primary clients were Fortune 100 multinational companies where he advised senior management on strategic planning and implementing merger and acquisition strategies. Prior to his activity in the management consulting business, Mr. Callow worked in sales and marketing for Tymshare, Inc. a venture funded and subsequent public company in the cloud and remote computing sector which was acquired by McDonnell-Douglas.
In 1986, he was the founding institutional investor in PAREXEL International Corporation, and continues as its Presiding Director and Chair of the governance committee. (Nasdaq: PRXL). From its inception and seed funding with four employees, PAREXEL is now the third largest clinical research organization worldwide generating revenues in excess of $ 1.8 billion annually with approximately 15,000 employees in 70 countries.
He is a lead investor in, or has served as, a Director of a number of other public and private companies, including ILEX Oncology, Inc. (Nasdaq: ILXO), a cancer pharmaceutical company acquired by Genzyme for $1 billion; MedAptus, Inc., a mobile computing provider of clinical, financial and administrative software solutions to the medical community; and PHT Technologies, Inc., a provider of mobile and Web-based technology solutions to the pharmaceutical industry focused on patient outcomes and clinical trials management. Other investment responsibilities included Glycofi Inc., (acquired by Merck, NYSE: MRK); HotJobs, Inc. (acquired by Yahoo, NasdaqGS: YHOO); iVillage, Inc. (acquired by NBC Universal, a subsidiary of General Electric, NYSE: GE); and Tektagen, Inc. (acquired by Charles River Laboratories, NYSE: CRL). Mr. Callow manages investments in CardioMems, Inc., a cardiovascular heart sensor device for the treatment of congestive heart failure, and Arthrosurface, Inc., a developer and manufacturer of advanced orthopedic devices. Mr. Callow is a past Director of Jobs for Massachusetts, a Massachusetts based non-profit organization comprised of business and political leaders including Governors Mitt Romney and Deval Patrick.
Dana is a Member of the National Board of Directors of the Leukemia and Lymphoma Society, a non-profit organization with $ 300 million in revenues advancing the research and treatment of blood cancers worldwide. He currently chairs its Therapeutic Acceleration Program Committee. Dana is a member of the Board of Trustees and is the Chairman of the Investment Committee at Tufts University. He is on the Board of Overseers at Tufts University Medical School. He has been a member of the Advisory Board of the Amos Tuck Center for Private Equity and Entrepreneurship at Dartmouth College since 1999.
Mr. Callow is a graduate of Tufts University and holds an MBA from the Amos Tuck School at Dartmouth College.

Andy Dorner, PhD
Vice President and Head of Global Translational Medicine
Takeda Pharmaceuticals

Dr. Dorner am a strong scientific leader and senior manager with 30 years of experience in biotech and big pharmaceutical environments in all stages of research and clinical development (early and late stage, companion diagnostics) and multiple therapeutic modalities (e.g., biologicals, small molecules, gene therapy and aptamers). He has built and led translational medicine organizations delivering high quality translational biomarker research and clinical biomarker results in multiple therapeutic areas including Oncology, Immunology, CVM and CNS. His experience managing bioanalytical groups implementing biomarker assays in the clinic has given him knowledge of multiple genomic technologies and patient characterization platforms for clinical application. His experience in technology assessments and external partnerships gives him a useful perspective on both innovation and its practical application. His translational research and clinical trial experience allows him to function as a bridge between research and the clinic in both forward and reverse translation directions. His focus is to direct and enable precision medicine approaches to therapies and drive innovative patient and disease characterization strategies delivering genomic and phenotypic data to inform R&D efforts. 

He is currently Vice President and Head of Global Translational Medicine at Takeda Pharmaceuticals.

Andrew M. Evens, DO, MSc, FACP
Director, Tufts Cancer Center; Chief, Division of Hematology/Oncology; Director, Lymphoma Program
Tufts Medical Center 

Following graduation with honors from the Chicago College of Osteopathic Medicine at Midwestern University, Dr. Evens completed his Internal Medicine residency at Lutheran General Hospital and he served an additional year as Chief Medical Resident. Dr. Evens subsequently completed his Hematology/Oncology fellowship at Northwestern University Feinberg School of Medicine and The Robert H. Lurie Comprehensive Cancer Center (RHLCCC). During fellowship, Dr. Evens also completed a Masters of Science in Clinical Investigation at Northwestern University. He is board certified in Hematology and Medical Oncology. Dr. Evens was a faculty member in the Division of Hematology/Oncology at Northwestern University and the RHLCCC through December 2010. He subsequently was a faculty member at the University of Massachusetts Medical School and the UMass Memorial Cancer Center (UMMCC) where he served as the Deputy Director of the UMMCC for Clinical and Translational Research. At Tufts MC, Dr. Evens is the Chief of the Division of Hematology/Oncology, Director of the Lymphoma Program, and Director of the Tufts Cancer Center.

Dr. Evens is a National and International expert in the biology, prognosis, and treatment of Non-Hodgkin lymphoma and Hodgkin disease/lymphoma. His clinical and research interests are dedicated wholly towards lymphoma, including bone marrow/stem cell transplantation (SCT). Over the past 10 years, Dr. Evens has been the principal investigator for >60 lymphoma clinical trials that have included phase I, II, and III studies- a number of which have been investigator-initiated clinical trials studying novel therapeutic agents for the treatment of lymphoma. Dr. Evens also maintains an active translational lymphoma laboratory studying lymphoma biology, signal transduction pathways, free radical-mediated biology, and the development of novel targeted agents for the treatment of lymphoma.

His work has been funded by the National Institutes of Health (NIH) and the National Cancer Institutes (NCI), including a prior 5-year K23 grant entitled 'Targeting the Mitochondria to Treat Lymphoma' and a currently funded R01 entitled 'MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Paradigm'. Dr. Evens has presented >120 research abstracts at National and International meetings (including >20 peer reviewed oral research presentations), written >10 book chapters, and he has published >110 manuscripts (including >75 original research articles) with a particular emphasis on the biology, prognosis, and treatment of lymphoma in a number of journals including the New England Journal of Medicine, Journal of American Medical Association, Blood, Journal of Clinical Oncology, Clinical Cancer Research, British Journal of Haematology, and Annals of Internal Medicine. Additionally, Dr. Evens is an Associate Editor for the British Journal of Haematology and on the Editorial Board of the Journal of Clinical Oncology.

Dr. Evens is a primary member of the select Hodgkin Lymphoma Working Group for the NIH/NCI Steering Committee and he is Chair of the Hematology Review Panel (R01) for the NIH/NCI VA Scientific Merit Review. He is also a “Core Member” of the Eastern Cooperative Oncology Group (ECOG) Lymphoma committee. Further, he is the ECOG Principal Investigator for several National clinical trials including high-risk follicular lymphoma (E2408, NCT01216683) and newly diagnosed (S0816) Hodgkin’s disease/lymphoma. Dr. Evens is also involved in several collaborations with investigators throughout the New England region, nationally, and internationally that include research on Hodgkin lymphoma, post-transplant lymphomproliferative disorders (PTLD), and epidemiological lymphoma research. He co-chairs an annual Chicago Lymphoma Symposium ( and he chairs a regional lymphoma collaborative educational effort through the Lymphoma Research Foundation (New England Lymphoma Rounds).

Meghan Gutierrez
Lymphoma Research Foundation

Meghan Gutierrez is Chief Executive Officer of the Lymphoma Research Foundation, the nation's largest non-profit organization devoted exclusively to funding lymphoma research and providing patients and health care professionals with critical information on the disease.
Gutierrez has focused her entire career in the government and philanthropic sectors, first as a Congressional staff member for one of the U.S. House of Representatives’ foremost leaders on health care policy, then shifting to the non-profit arena, working on an array of health-related issues, ranging from mental health parity and rare disease awareness to medical technology and the treatment of chronic disease. A specialist in government relations and communications, she has served as a health policy and communications advisor for several non-profit and educational institutions, including Columbia University and the Partnership for a Drug-Free America.

In 2008, Gutierrez joined the Lymphoma Research Foundation as its chief program, policy and communications officer. She was a driving force behind programs such as the country’s only Adolescent and Young Adult Lymphoma Initiative and development of the first mobile app for people with lymphoma. She became chief executive officer in 2014. In this role Gutierrez represents the Foundation before a number of audiences, including the U.S. Congress, Department of Defense, Food and Drug Administration and National Institutes of Health. She has written and lectured extensively about the needs of lymphoma patients and served on committees and panels of the American Society of Clinical Oncology, American Society of Hematology, Institute of Medicine, and National Cancer Institute, among others.
Ms. Gutierrez earned her Bachelor of Arts degree from the University of Iowa.

Deborah T. Kochevar, DVM, PhD, DACVCP
Dean and Henry and Lois Foster Professor
Tufts Cummings School of Veterinary Medicine

Deborah T. Kochevar, DVM, PhD, DACVCP is Dean and Henry and Lois Foster Professor at the Cummings School of Veterinary Medicine at Tufts University.  She received a Doctor of Veterinary Medicine degree from Texas A&M University and a PhD degree in cellular and molecular biology from the University of Texas, Southwestern Graduate School of Biomedical Sciences. After completing an NIH National Research Service Award Fellowship, she joined the faculty at Texas A&M University where she remained until 2006. Dr. Kochevar is a former Congressional Science Fellow to the Senate Labor and Human Resources Committee, a diplomate and past president of the American College of Veterinary Clinical Pharmacology and is active in the American Veterinary Medical Association, having chaired its Council on Education and the Educational Commission for Foreign Veterinary Graduates.  She completed service as president and chair of the Board of Directors of the Association of American Veterinary Medical Colleges in 2013. Dr. Kochevar has published in peer-reviewed research and teaching journals and garnered extramural funding for her work. She has won college, university and national level teaching awards and has developed special interests in international aspects of health education, including the importance of inter-professional One Health curricula.  As a board-certified veterinary clinical pharmacologist, she understands the promise and the challenge of utilizing naturally occurring companion animal disease to advance our understanding of cancer. One Health insights encourage innovation across inter-professional medical and veterinary lines and potentially decrease the time and costs associated with bringing cancer therapeutics to human and animal patients.

Neil Maniar, MPH, PhD
Vice President, Health Systems, New England Division
American Cancer Society

As the New England Division’s Health Systems leader, Neil leads a team of more than 40 staff to work with state-based, hospital, and primary-care health systems to further the Society’s mission to save lives from cancer. His team works within health care systems to increase utilization of cancer prevention strategies and cancer screening tests; to reduce barriers to care for cancer patients; and to engage health care organizations in fighting cancer through the Society’s advocacy, corporate, community, and fundraising initiatives. Neil serves as adjunct faculty at the Bouvé College of Health Sciences at Northeastern University where he teaches Health Education, Program Planning, and Urban Community Health Assessment. Prior to joining the Society, Neil served as the director of Health Equity Programs in the Brigham and Women’s Hospital Center for Community Health and Health Equity. He was also the founding director of the Massachusetts Youth Violence Prevention Program at the Massachusetts Department of Public Health and the founding chair of the Massachusetts Coalition for Youth Violence Prevention. He currently serves on the Board of Directors of the Massachusetts Public Health Association.  Neil received his PhD from the Johns Hopkins University Bloomberg School of Public Health in 2005. In 1998, he earned his Master’s in Public Health (MPH) with distinction from the Yale University School of Public Health, and in 1994, he received his Bachelor’s degree from Connecticut College with a double major in English and Zoology.  

Anthony P. Monaco, MD, PhD
Tufts University

Anthony P. Monaco has served as president of Tufts University since August 1, 2011.  Under his leadership, the university is implementing a comprehensive strategic plan and is actively engaged in long-term capital planning. In concert with President Monaco’s commitment to broaden access to a Tufts education and contain costs, the university has also successfully implemented university-wide initiatives to advance effectiveness in its administrative management.  President Monaco served as pro-vice-chancellor for planning and resources at Oxford University from 2007 until his arrival at Tufts.

A distinguished geneticist, Dr. Monaco received his undergraduate degree from Princeton University, and his M.D. and Ph.D. through Harvard Medical School’s Medical Scientist Training Program. He directed Oxford’s Wellcome Trust Centre for Human Genetics from 1998-2007 and was then appointed as pro-vice-chancellor for planning and resources; in that role, he developed and led strategic-planning initiatives for academic programs, capital improvements and budgeting and resource allocation there.

President Monaco chairs the Steering Committee of the Talloires Network, whose more than 350 member institutions around the world are committed to advancing civic engagement in higher education. He is President of the Association of Independent Colleges and Universities of Massachusetts and serves on the boards of Cummings Foundation; the Omidyar-Tufts Microfinance Fund; the Salesianum School in Wilmington, Delaware; Tufts Medical Center; and WGBH.

President Monaco was elected to the European Molecular Biology Organization (EMBO) in 2006, and is a fellow of the Academy of Medical Sciences (U.K.) and the Royal Society of Medicine and a member of the Association of American Physicians.

Tariq Mughal, MD
Vice President, Medical Affairs
Foundation Medicine

Tariq Mughal qualified in medicine at St George’s Hospital Medical School in London (UK), followed by postgraduate training in Hematology, Medical Oncology and Stem Cell Transplantation at the Imperial College London (Hammersmith Hospital) and the University of Colorado School of Medicine, Denver. He is Vice President, Medical Affairs at Foundation Medicine Inc., Professor of Haematology/Oncology at the University of Buckingham (UK), Clinical and a faculty member at the Tufts University Medical Center, Boston. His principal research interests are in cancer genomics and myeloid malignancies. He has published over 125 peer reviewed papers, 33 cancer textbook chapters and 14 cancer books. He is the recipient of a number of awards, including those from the UK Royal College of Physicians, American College of Physicians, Swiss humanitarian groups and in 2014 was awarded the Highly Commendable British Medical Association Cancer Book Award.

Abhi Pandey, MD
Chief Physician Executive

Abhi Pandey is the Physician Executive at Syapse, a position he has held since 2014. Abhi is a medical doctor by training with extensive informatics experience. He received his medical degree at Georgetown University Medical Center, where he worked on the Georgetown Database of Cancer, an effort funded by the NCI’s Cancer Bioinformatics Grid (CaBIG) initiative. Abhi’s work has been published in the Journal of the American Medical Association, Frontiers in Genetics, and the Washington Post. 

Gene & Lorraine Sacco
Reid R. Sacco Adolescent and Young Adult Cancer Alliance

Lorraine and Gene founded the Reid R Sacco AYA Cancer Alliance shortly after their son, Reid, lost his courageous two-year battle with rhabdomyosarcoma in April 2005, at age 20.  Just a few months later, on what would have been Reid’s 21st birthday, Lorraine and Gene launched the first Reid’s Ride 28-mile Bike-a-thon, a bicycling event for all ages and abilities, designed to raise awareness and funds to fight cancers striking adolescents and young adults (AYAs).  Reid’s Ride instantly became an annual event, held the third Sunday each July, with 2016 marking the 12th Reid’s Ride.

Funds raised through Reid’s Ride, Reid’s Run and other events have been instrumental in establishing innovative AYA cancer programs and clinics, including those at Tufts Medical Center (Boston) and at Connecticut Children’s Medical Center (Hartford).  Today, these programs are collaborating with hospitals and centers across New England and across the nation in addressing the gaps in the care and treatment of AYA cancer patients and survivors, and in access to clinical trials.  The funds raised from these events have also supported a number of studies and clinical trials targeted at AYA cancers, and have supported physician training in the unique issues facing AYA cancer patients and survivors. 

Today, the Reid R Sacco AYA Cancer Alliance is an all-volunteer organization of more than 300 members, a large proportion of which are young adults.  The Alliance is the engine behind Reid’s Ride and other fund-raising events, and has become an influential advocate and voice for AYA Cancer patients and survivors.
Reid was an accomplished athlete, musician and student with a magnetic personality, infectious energy, and gifted intellect.  When cancer claimed his life, Reid’s family and friends suffered a profound, life-long loss, as did society as a whole.  Reid was clearly on a path to make remarkable contributions to this world, and that potential was lost. 

Accepted to Columbia University where he intended to study for a degree in engineering, Reid had to defer the start of his freshman year twice to undergo aggressive chemotherapy, radiotherapy and surgery.  It was during Reid’s cancer treatment from 2003 to 2005 that the Sacco family learned first-hand about the tragic gaps and grim survival statistics facing adolescents and young adults (AYAs) diagnosed with cancer.  It was Reid himself who, while recovering from the last of several disabling surgeries, began planning an organization that would have the mission to close those gaps and to change the outlook for AYA cancer patients like himself.  After Reid’s death, Lorraine and Gene carried on Reid’s dream of “altering the course of AYA cancers”.   

Also carrying on Reid’s legacy is Reid’s brother, Weston, who graduated medical school in 2015.  As an Emergency Medicine resident at the University of Massachusetts Medical Center, and knowing the importance of early diagnosis in AYA cancer survival, Weston is especially diligent in making sure that cancer is thoroughly considered in every differential diagnosis, regardless of the age of his patients. 
Lorraine A. Sacco is a graduate from Salem State University.  She has been a health care professional for more than 30 years and presently works as a Medical Technologist in Core Lab at MGH.  But her most important calling was a devotion to her two sons, Reid and Weston, and to their intellectual, moral and physical development.  Always active in coming to the aid of others, she uses her gregarious personality to bring others together to enrich the world around us.  Recent honors include the 2011 Rotary Citizen of the year and the 2014 Honoree of “The One Hundred” at MGH.  An avid walker and cyclist, Lorraine has a deep passion for Boston, Kennebunk and the ocean, where she frequently cycled with her sons.  Today Lorraine still finds cycling along the ocean as a “little piece of Heaven”.

Gene graduated with a B.A. in Biology from the University of Massachusetts, and with an MBA from Northeastern University. Gene R. Sacco has worked in the biotechnology industry for more than 25 years, and is currently Director of Operations Management at Pfizer, Inc.  Outside of work hours and when not working to help grow the AYA Cancer Alliance, Gene enjoys piano, photography, cycling and tennis.  He infected both his sons with the qualities of a gentleman, and with his passions for writing, music and science.
Weston D. Sacco, MD, is a graduate of Lynnfield High School, and holds a B.S. from Davidson College (Davidson, NC) and his MD from Tulane School of Medicine (New Orleans, LA).  He is currently an Emergency Medicine Resident at the University of Massachusetts Memorial Medical Center.  He lives in Newton with his wife, Lindsay, an Anesthesiology Resident at Beth Israel Hospital (Boston).  In his rare spare time, Weston enjoys traveling with Lindsay, cycling and playing tennis with his Dad.  His “little piece of heaven” is time in Kennebunk, where he spent many summers growing up with his brother, Reid.

Dvorit Samid, PhD
Senior Vice President, Medical Affairs

Dr. Samid is heading the Global Oncology Medical Affairs program at NantKwest, an immunotherapy company developing a novel "off-the-shelf" engineered Natural Killer (NK) cell platform and playing a lead role in the Cancer MoonShot 2020 program - aiming to accelerate personalized, next generation Immunotherapy for patients with cancer. Prior to joining NantKwest in 2015, Dr. Samid lead Oncology Medical Affairs of other pharmaceutical companies including ImClone Systems, Abraxis Oncology and Hoffman-La Roche. She served also as Associate Professor at the University of Virginia’s Cancer Center and Section Chief at the National Cancer Institute. 

Harry P. Selker, MD, MSPH
Executive Director, Institute for Clinical Research and Health Policy Studies; Pratt Diagnostic Center Primary Care Physician; Dean, Clinical and Translational Science Institute; Professor of Medicine
Tufts University, Tufts Medical Center 

Harry P. Selker, MD, MSPH is Dean of Tufts Clinical and Translational Science Institute (CTSI) ( at Tufts University, and Executive Director of the Institute for Clinical Research and Health Policy Studies ( at Tufts Medical Center.  As Dean of Tufts CTSI, he provides leadership and is responsible for the programs and infrastructure that support clinical and translational research at the Tufts University Schools and affiliated hospitals, and other academic, community-based and industry CTSI partners. He practices medicine at Tufts Medical Center.

Dr. Selker‘s research focuses on the development of treatment strategies, decision aids, and systems aimed at improving medical care.  He is known for a series of studies of the factors influencing emergency cardiac care and for development of "clinical predictive instruments," mathematical models that are used as decision aids.  They provide emergency physicians and paramedics with predictions for their patients’ likely cardiac diagnoses and outcomes for real-time use in clinical care.  This has included conduct of multiple large national clinical effectiveness trials that have demonstrated better treatment and clinical outcomes for patients with acute coronary syndromes. Additionally, Dr. Selker has done research to advance clinical study design, execution, issues around informed consent, data analysis, mathematical predictive modeling of medical outcomes, and comparative effectiveness research.  

Dr. Selker also has contributed to health services and health policy research, with a focus on translational research that ultimately has impact on the public’s health.  He has advised policymakers around healthcare delivery and medical research, including the House and Senate authors of the Affordable Care Act.  Nationally, Dr. Selker has served as president of the Society of General Internal Medicine, of the Society for Clinical and Translational Science, and of the Association for Clinical Research Training, and serves on boards of organizations and Federal agencies.  He is currently President of the Association for Clinical and Translational Science and Chairman of the Clinical Research Forum.  

Randy Schwartz, MSPH
National Senior Vice President, Health Systems - Cancer Control 
American Cancer Society 

Randy Schwartz, MSPH, is Senior Vice President, Health Systems – Cancer Control for the American Cancer Society. He has over thirty years’ experience in health promotion/disease prevention in state health department and voluntary health organizations with an emphasis on chronic disease prevention and control, cancer control and community-based health promotion.  He has served in this role at ACS since March 2015.  In this position, he is responsible for providing leadership in the development, execution and evaluation of organizational strategy for cancer control/public health systems policy and practice initiatives, including state-based systems, hospital systems, primary care systems and other community based systems.  He provides leadership in the strategic, integrated, comprehensive planning for and execution of system policy and practice initiatives at all levels of the organization; and ensuring initiatives are evidenced-based, regularly evaluated for impact and quality improvement, and consistent with the goals and objectives set by the National Board of Directors.  

Prior to this, he served as Vice President for Health Systems for the ACS, New England Division (2000-2015), implementing the Division's Program of Work for Cancer Prevention, Cancer Detection, and Quality of Life/Patient reduce the burden of cancer on the communities and citizens in the six-states of New England. Before this work at ACS, he was Director of the Division of Community and Family Health of the Maine Bureau of Health (now Maine CDC), where he worked for seventeen years, fifteen of which were in a senior position as a Division Director. In that role, he directed all chronic disease prevention and control and health promotion programs (including cancer control, cvd prevention, tobacco prevention and control and community health promotion), as well as the maternal and child health and public health nursing programs. In these positions he has directed the implementation and evaluation of health promotion/disease prevention interventions (with a concentration in cancer prevention and control/tobacco control) in multiple settings including community, worksite, health care and public policy. 

Randy has participated on numerous national review panels and committees, including the Institute of Medicine Committee to Review the CDC Centers for Research and Demonstration of Health Promotion and Disease Prevention; was a member or Chair of the grant review panels for CDC’s, Prevention Research Centers over a period of fifteen years; and served as a reviewer on numerous NIH and NCI grant review panels. He has served as a reviewer for the Cancer Prevention & Research Institute of Texas (CPRIT) and numerous other grant review and advisory panels. 

He has authored or co-authored numerous articles on health promotion and chronic disease prevention. Randy is the Founding Editor of the journal, Health Promotion Practice, a journal of the Society for Public Health Education. He has been awarded the Society for Public Health Education’s Distinguished Fellow Award, the Society’s highest honor.

Randy lives in Manchester, Maine with his wife, Kini Tinkham a nurse- health care consultant in family planning quality improvement, intimate partner violence, and direct clinical services, along with their lab-boxer mix dog, Sadie.  They have two adult children - Haley (a graduate of Tufts University MPH program and a MNP Nurse Practitioner living in MA) and Taylor (an epidemiologist MPH graduate of the Tufts University, living in San Francisco, CA).

Tracey F. Weisberg, MD
President and Lead Physician
New England Cancer Specialists 

Dr. Weisberg was born in Buffalo, NY. She went to Mount Holyoke College in Western Mass (Magna Cum Laude, Biochemistry) and received her Medical Degree from SUNY Stony Brook School of Medicine on Long Island, NY. Residency in Internal Medicine was at The Mount Sinai Medical Center in NYC and Hartford Hospital in CT. She did her Fellowship in Research and Clinical Oncology at Yale University. She moved to Maine in the late 1980s, working as a Staff Physician at Martin’s Point, and doing research in Solid Tumor Biology at the Maine Cytometry Research Institute. This involved joint projects with New England Cancer Specialists and eventually led to her joining the organization.

Dr. Weisberg currently is the president and lead physician at New England Cancer Specialists. She has worked in the field of medical oncology for more than 25 years. Professionally, her areas of interest are in breast cancer treatment, cancer survivorship, clinical research in breast cancer, and the molecular genetics of breast cancer predisposition. She is the immediate past president of the Northern New England Cancer Society. She serves on the American Society of Clinical Oncology State Affiliates Council. She is on the board of directors of the Hospice of Southern Maine.

She lives in Falmouth with her husband and enjoys reading, golf, long walks and visiting with her three grown daughters Anna, Elizabeth, and Leah. When free from clinical responsibilities, she loves to travel both within and outside of the USA with recent trips to Europe, South America, and Hawaii. She also is a board member for Portland Stage Company.